MS: Busting the Myths
November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
November 16, 2022 | Advocacy, Covid-19, Treatments
Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]
November 16, 2022 | Advocacy, Life with MS, Media
Recently, MSNZ made a submission to the Accessibility for New Zealanders Bill. The intention of the proposed bill is to establish “a new legislative framework that addresses systemic accessibility barriers that prevent disabled people, tāngata whaikaha and their whānau, and […]
November 9, 2022 | Uncategorised
Malcolm Rickerby is what can only be described as the ultimate volunteer. The countless hours and passion he has dedicated to Multiple Sclerosis New Zealand since the 1970s has not been matched by any other in recent memory. Malcolm has […]
November 9, 2022 | Advocacy, Media
This morning, 9th November 2022, MSNZs President, Neil Woodhams and petition submitter, Joan Perry made an oral presentation to the Health Select Committee calling for them to make aHSCT an available treatment option in NZ. It was live streamed on […]